Veru Inc

-0.13 (-1.15%)

Veru Submits EUA Application To FDA For Treatment Of COVID-19 Patients At High Risk For ARDS

Published: 06/07/2022 10:43 GMT
Veru Inc (VERU) - Veru Submits Emergency Use Authorization (eua) Application to U.S. FDA for Sabizabulin, Its Novel, Oral Antiviral and Anti-inflammatory Drug Candidate for Hospitalized Covid-19 Patients at High Risk for Ards.
Veru- is in Discussions With Other Regulatory Agencies Around World Regarding Emergency Use Authorization for Sabizabulin Including European Medicines Agency.
Veru Inc- Prepares for U.S. Commercial Launch If Eua is Granted.
Veru- Eua Submission Follows Positive Phase 3 Covid-19 Clinical Trial in Which Sabizabulin Showed 55.2% Reduction in Death in Hospitalized Covid-19 Patients.